Xin Lang Cai Jing·2025-11-26 07:27Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business segments include: - Formulations: 63.06% - CDMO: 18.59% - Heparin sodium and low molecular weight heparin raw materials: 16.05% - Others: 2.30% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Renminbi [3]. Market Activity - On November 26, the stock price of Hepalink increased by 0.51%, with a trading volume of 36.7143 million yuan and a turnover rate of 0.25%, leading to a total market capitalization of 17.402 billion yuan [1]. - The stock has seen a net outflow of 223,600 yuan from major funds today, with a ranking of 74 out of 159 in its industry [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.0093 million shares, an increase of 691,700 shares compared to the previous period [9]. Dividend Information - Since its A-share listing, Hepalink has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].